Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor

International Journal of Cancer

Volumn 123, Issue 7, 2008, Pages 1491-1498

  Oba, Masaru ^a   Miwa, Koichi ^a   Fujimura, Takashi ^a   Harada, Shinichi ^a   Sasaki, Shozo ^a   Hattori, Takanori ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Chemoprevention; COX 2; Duodenogastric reflux; Gastric carcinogenesis; Glandular stomach

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; RNA; MESSENGER RNA; PRIMER DNA; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGES PROTEIN, RAT; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG SELECTIVITY; DUODENOGASTRIC REFLUX; ENZYME ACTIVITY; FIBROBLAST; GASTRITIS; GENE EXPRESSION; IMMUNOREACTIVITY; INCIDENCE; INFLAMMATION; MACROPHAGE; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RAT; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH MUCOSA; STROMA CELL; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; FISCHER 344 RAT; GENETICS; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR;

ANIMALS; BASE SEQUENCE; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DNA PRIMERS; DUODENOGASTRIC REFLUX; GASTRIC MUCOSA; IMMUNOHISTOCHEMISTRY; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; THIAZINES; THIAZOLES;

EID: 50549097538     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23742     Document Type: Article

References (49)

1. Miwa K, Hattori T, Miyazaki I. Duodenogastric reflux and foregut carcinogenesis. Cancer 1995;75:1426-32.
2. Domellöf L, Janunger K-G. The risk for gastric carcinoma after partial gastrectomy. Am J Surg 1977;134:581-4.
3. Fisher SG, Davis F, Nelson R, Weber L, Goldberg J, Haenszel W. A cohort study of stomach cancer risk in men after gastric surgery for benign disease. J Natl Cancer Inst 1993;85:1303-10.
4. Lundegardh G, Adami H-O, Helmick C, Zack M, Metrik O. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988;319:195-200.
5. Toftgaard C. Gastric cancer after peptic ulcer surgery. A historic prospective cohort investigation. Ann Surg 1989;210:159-64.
6. Taylor PR, Mason RC, Filipe MI, Vaja S, Hanley DC, Murphy GM, Dowling RH, McColl I. Gastric carcinogenesis in the rat induced by duodenogastric reflux without carcinogens: morphology, mucin histochemistry, polyamine metabolism, and labeling index. Gut 1991;32: 1447-54.
7. Miwa K, Hasegawa H, Fujimura T, Matsumoto H, Miyata R, Kosaka T, Miyazaki I, Hattori T. Duodenal reflux through the pylorus induces gastric adenocarcinoma in the rat. Carcinogenesis 1992;13:2313-16.
8. Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, Hattori T. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer 1996;67:269-74.
9. Mukaisho K, Miwa K, Kumagai H, Bamba M, Sugihara H, Hattori T. Gastric carcinogenesis by duodenal reflux through gut regenerative cell lineage. Dig Dis Sci 2003;48:2153-8.
10. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclogenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
11. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
12. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
13. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
14. Zimmermann KC, Sarbia M, Weber A-A, Borchard F, Gabbert HE, Schrör K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
15. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ, III. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
16. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275:32783-92.
17. 2 biosynthesis. J Biol Chem 2000;275:32775-82.
18. Tanikawa N, Ohmiya Y, Ohkubo H, Hashimoto K, Kangawa K, Kojima M, Ito S, Watanabe K. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun 2002;291:884-9.
19. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
20. Delta;716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
21. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
22. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
23. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
24. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
25. Delta;716 mouse intestinal polyps. Cancer Res 2002;62:506-11.
26. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
27. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-12.
28. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohta T, Miwa K. A COX-2 inhibitor prevents esophageal inflammation-metaplasia- adenocarcinoma sequence in rats. Carcinogenesis 2005;26:565-70.
29. Yabe T, Honma M, Katsuki S, Luetzen L, Wiegleb J, Pueschner H, Lehmann H. Oral toxicity studies of meloxicam in rats. Oyo Yakuri/Pharmacometrics 1997;53:29-49.
30. Littler ER, Gleibermann E. Gastritis cystica polyposa (Gastric mucosal prolapse at gastroenterostomy site, with cystic and infiltrative epithelial hyperplasia). Cancer 1972;29:205-9.
31. Franzin G, Novelli P. Gastritis cystica profunda. Histopathology 1981;5:535-47.
32. Haatori T, Helpap B, Gedigk P. The morphology and cell kinetics of pseudopyloric glands. Virchows Arch B Cell Pathol Incl Mol Pathol 1982;39:31-40.
33. Cornaggia M, Capella C, Riva C, Finzi G, Solcia E. Electron immunocytochemical localization of pepsinogen I (PgI) in chief cells, mucous-neck cells and transitional mucous-neck/chief cells of the human fundic mucosa. Histochemistry 1986;85:5-11.
34. Katsuyama T, Spicer SS. Histochemical differentiation of complex carbohydrates with variants of the concanavalin A-horseradish peroxidase method. J Histochem Cytochem 1978;26:223-50.
35. Koch HK, Lesh R, Cremer M, Oehlert W. Polyps and polypoid foveolar hyperplasia in gastric biopsy specimens and their cancerous prevalence. Front Gastrointest Res 1979;4:183-91.
36. 2 production in the rat adjuvant-induced arthritis model. J Immunol 2003;170:4738-44.
37. Rees van BP, Saukkonen K, Ristimäki A, Polkowski W, Tytgat GNJ, Drillenburg P, Offerhaus GJA. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002;196:171-9.
38. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006;1:119-50.
39. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D, Lin D, You W. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006;130:1975-84.
40. Nam KT, Hahm K-B, Oh S-Y, Yeo M, Han S-U, Ahn B, Kim Y-B, Kang JS, Jang DD, Yang K-H, Kim D-Y. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin Cancer Res 2004;10:8105-13.
41. Magari H, Shimizu Y, Inada K, Enomoto S, Tomeki T, Yanaoka K, Tamai H, Arii K, Nakata H, Oka M, Utsunomiya H, Tsutsumi Y, et al. Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Biochem Biophys Res Commun 2005;334:606-12.
42. Hahm KB, Song YJ, Oh TY, Lee JS, Surh Y-J, Kim YB, Yoo BM, Kim JH, Han SU, Nahm KT, Kim M-W, Kim DY, et al. Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model; Is it possible? J Biochem Mol Biol 2003;36:82-94.
43. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AHC, Sung JJY. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200.
44. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2(COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-47.
45. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-92.
46. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grösch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;67:1469-78.
47. Wong BC-Y, Jiang XH, Lin MCM, Tu SP, Cui JT, Jiang SH, Wong WM, Yuen MF, Lam SK, Kung HF. Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Gatroenterology 2004;126:136-47.
48. Liu J-F, Zhang S-W, Jamieson GG, Zhu G-J, Wu T-C, Zhu T-N, Shan B-E, Drew PA. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. Int J Cancer 2008;122: 1639-44.
49. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 2004;23:1669-78.